Hematology

Breast Cancer, Non-metastatic

Questions discussed in this category

How would you manage a patient who develops acute stroke during neoadjuvant chemotherapy with KEYNOTE-522 for Stage III triple negative breast cancer?

Would you continue KEYNOTE-522 neoadjuvant therapy? The patient has a PMH of sarcoidosis with no stroke risk factors. No residual deficits.

1 Answer available

Do you recommend prophylactic anticoagulation to pregnant women undergoing chemotherapy for breast cancer?

Since both pregnancy and cancer are risk factors for VTE, is there data to guide when or if we should prophylactically anticoagulate? If so, what shou...

1 Answer available

Would you use aspirin 81 mg for VTE prophylaxis in patients on adjuvant tamoxifen/SERMs?

Is there data that it actually helps?

1 Answer available

Do you discontinue anti-hormonal therapy if a high-risk ER+ HER2- localized breast cancer patient develops blood clots on anti-hormonal therapy?

How would you approach a patient who is intolerant of AI and develops thrombosis while on SERM?

3 Answers available

How do you manage endocrine therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?

1 Answer available

Papers discussed in this category

Lancet (London, England), 2014-03-22

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

The New England journal of medicine, 2011-06-23

Exemestane for breast-cancer prevention in postmenopausal women.

Journal of the National Cancer Institute, 2005-09-07

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

The New England journal of medicine, 2016-07-21

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Journal of the National Cancer Institute, 2010-07-07

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

J Natl Cancer Inst, 2006 Jul 5

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

J. Natl. Cancer Inst., 2010-07-07

Tamoxifen and the factor V Leiden mutation.

J. Clin. Oncol., 2003-10-01

Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.

J Natl Cancer Inst, 2011 Jul 09

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Br J Clin Pharmacol, 2020 Jun 02

Effect of low-dose aspirin on health outcomes: An umbrella review of systematic reviews and meta-analyses.

PloS one, 2017

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.

Circulation, 2016-03-29

Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991 Feb

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.

Journal of stroke, 2020 Jan 31

Hematology

Breast Cancer, Non-metastatic

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematology